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Letters
Interpretation of the Mwanza
and Rakai STI trials
Editor – In addition to discussing sexual
behaviour aspects of the Mwanza and
Rakai trials of interventions against
sexually transmitted infection (STIs),
Christopher Hudson also raises a
number of points relating to STI control
in developing countries that warrant
further discussion. Hudson states that
low prevalences of infection with HIV
and herpes simplex virus (HSV), as
in Mwanza, may mark the early stages
of an HIV epidemic, and that high
prevalences of these two viruses indicate
a mature epidemic (1). However, data
from the Mwanza study population
show that the prevalence of HSV-2
antibodies, adjusted for age and sex,
is high and very similar to the mature
HIV epidemics in Rakai and Masaka
referred to by Hudson (2). Also Hudson
states that there was no association
between HIV and HSV in an earlier
study in Durban whereas, in fact,
HSV was identified as a significant risk
factor for HIV early on in the epidemic,
particularly in young women (3).
Hudson suggests that the Rakai trial
should in some way be termed the gold
standard. However, there are still some
points about the Rakai trial that remain
uncertain. Firstly, there must be some
doubt about whether or not subjects
actually took the mass treatment. Anti-
biotic levels were not tested in either
blood or urine. Although medication
was administered through direct obser-
vation, the question remains whether
tablets could have been ‘‘pocketed’’ by
study subjects either to be used later
on if they became symptomatic or sold
as a source of revenue. The cost of 1 g
of azithromycin alone at the time of the
trial would have been in the region of
US$ 10, more than the weekly wage
for the majority of the trial participants.
Many of those in the trial would have
been in stable monogamous relation-
ships at very low risk of STI and HIV
and would see little point in taking
unnecessary medication and risking
possible side-effects.
Secondly, asMichel Alary points out
in the accompanying commentary (4),
mobile high-risk individuals may have
been missed in Rakai. Coverage of the
study was less than 80%, and one is
reminded of the 80/20 rule that states
that 20% of the population contributes
at least 80% of the net transmission
potential of infectious agents (5). If the
subjects in the trial did not include these
20% high-risk core group transmitters
it would not be surprising that the trial
had little effect on STIs and HIV.
Furthermore, the treatments took one
month per cluster to complete which
would have allowed plenty of time for
new infections or reinfection from
an untreated contact.
Hudson also states that more basic
studies should have been done looking
at the efficacy of single dose ciproflox-
acin and azithromycin in curing chronic
gonorrhoea. Differentiation of gonor-
rhoea into acute and chronic stages is not
usually recognized by current STI
textbooks and WHO STI treatment
algorithms. Chronic gonorrhoea is,
however, a common diagnosis in coun-
tries of the former Soviet Union and
Mongolia where non-specific urethritis/
chlamydia has not always been recog-
nized (6). Azithromycin is accepted as
an effective treatment for chlamydia.
The point that Hudson raises about
behaviour change as a factor in reducing
STI prevalence in Mwanza is an im-
portant one. While the Mwanza study
reported on numbers of sexual partners,
it may be that other sexual behaviours
not recorded in Mwanza — such as
continuing to have sex despite the
presence of genital lesions or other
symptoms — might be relevant in
driving large-scale heterosexual HIV
epidemics (7).
What theMwanza and Rakai studies
have shown is that improving STI
control for HIV prevention is not
straightforward and requires different
approaches in different populations.
Any search for a ‘‘magic bullet’’ is likely
to be a lengthy one and should be
viewedwith scepticism. Perhaps a return
to the basic principles of STI control,
involving comprehensive case manage-
ment to be implemented wherever STI
treatments are dispensed, might be
a more appropriate overall STI control
strategy and one that could be adapted
to local conditions. n
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Interpretation of the Mwanza
and Rakai STD trials
Editor – There has been considerable
discussion of the contrasting results
of the Mwanza and Rakai trials of
interventions against sexually
transmitted diseases (STDs). The
Mwanza trial showed that improved
STD treatment services as recom-
mended by WHO led to a 38%
reduction in HIV incidence (1), while
in the Rakai trial mass treatment for
STDs failed to reduce HIV infection (2).
Several thoughtful reviews have
discussed these findings, and in June
last year scientists from the two trials
combined forces to present their views
(3). A number of explanations have been
put forward: STDs may play a less
important role in HIV spread in mature
HIV epidemics; incurable STDs,
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including herpes, may have been more
common in Rakai; and rounds of mass
treatment in Rakai may have been
followed by rapid reinfection.
In a recent contribution to the
Bulletin, Dr Hudson puts forward an
alternative view (4), arguing that the trial
results failed to demonstrate that STD
treatment reduces HIV transmission,
and that the HIV effect seen in Mwanza
was due instead to behavioural change.
Unfortunately, while we welcome open
debate, we do not think Hudson’s paper
will do much to illuminate the present
controversy, since most of his assertions
are inconsistent with published data.
Hudson argues that the HIV effect
in Mwanza could not have been due to
improved STD treatment because the
effect on STDs was only ‘‘modest’’.
However, the prevalence of sympto-
matic urethritis was cut by half, and
newly acquired syphilis by at least 40%
(5). The prevalence of chancroidwas not
measured, but the syphilis data suggest
that the prevalence of genital ulcer
disease (GUD) was reduced very sub-
stantially. There is now overwhelming
evidence that GUD plays a key role in
HIV spread in Africa, and it seems very
likely that the reduction in GUD in
Mwanza made an important contribu-
tion to the observed decrease in HIV
incidence. Interestingly, the Rakai inter-
vention had no effect at all on newly
acquired syphilis. The reported effect on
syphilis refers to the prevalence of
positive serology, and this fell due to
treatment of positives at mass treatment
rounds. However, most of these were
low titre cases, probably representing
latent infections that are of little rele-
vance to HIV transmission.
Hudson suggests the HIV impact in
Mwanza resulted from behavioural
change due to counselling of STD
patients at clinics or to information
campaigns in the villages. The latter
focused on informing the community
about the improved treatment services,
and it seems very unlikely that this would
have had a measurable effect on sexual
behaviour. Hudson identifies one
variable in the published data that seems
to show a difference between the
intervention and comparison commu-
nities in women, but this is an isolated
and non-significant finding and is not
borne out in other variables or in men.
The overwhelming impression from
the many behavioural variables exam-
ined was that there was no difference
between the trial arms. Promoting sexual
abstinence or condom use until treat-
ment is complete is an important
component of STD case management.
However, the idea that this could have
a substantial impact on the overall level
of HIV transmission in the community,
even if some patients were in the
viraemic phase of primary HIV infec-
tion, seems fanciful. Moreover, condom
uptake in these rural areas at the time
of the trial was extremely low, despite
counselling, and only 0.9% of STD
patients accepted free condoms.
Finally, Hudson misinterprets
recently published data from Mwanza
on population-attributable fractions
(PAF) of HIV due to symptomatic
STDs (6). The fact that in the compar-
ison arm 40% of HIV seroconversions
inmen were attributable to self-reported
STD syndromes, but only 12% in the
intervention arm, strongly supports
the hypothesis that reductions in symp-
tomatic STDs led to a reduction in HIV.
Calculations show that this difference
would explain nearly 80% of the ob-
served effect on HIV (6). The striking
contrast between the strong association
of GUD and HIV in the comparison
arm (OR = 14.8) and lack of association
in the intervention arm (OR = 1.1)
is very difficult to explain other than
through an effect of treatment on GUD
duration and hence on HIV acquisition.
Data from Rakai showed a much lower
PAF due to treatable STDs.
Hudson suggests a trial of counsel-
ling of STD patients alone versus
counselling and improved STD treat-
ment. This is ethically unacceptable as
it would mean actively withholding care
for harmful infections from patients
attending improved facilities in the
control communities.
Drs O’Reilly & Gerbase, in their
accompanying commentary (7), stress
that STD treatment is not a ‘‘magic
bullet’’, but one of many approaches
needed for HIV prevention. We fully
agree. As stated in the original Mwanza
report: ‘‘Educational interventions,
aimed at modifying risk behaviour ...
remain an important priority for national
AIDS control programmes. However,
our results suggest the importance
of complementing these activities with
improvements to STD treatment
services’’ (1). That STDs are an impor-
tant risk factor for HIV transmission
is beyond question. Effective STD
management has been identified as
a fundamental component of primary
care, not only because of the effect
of STDs on HIV but their many other
adverse effects. While continuing to
promote behavioural change, AIDS
control programmes must continue
to ensure that this basic provision is
available to all. n
Richard Hayes
Professor of Epidemiology and International
Health
Heiner Grosskurth
Senior Lecturer in Infectious Disease
Epidemiology
David Mabey
Professor of Communicable Diseases
London School of Hygiene and Tropical
Medicine,
Keppel Street, London WC1E 7HT, England
(email: richard.hayes@lshtm.ac.uk)
1. Grosskurth H et al. Impact of improved
treatment of sexually transmitted diseases on
HIV infection in rural Tanzania: randomised
controlled trial. Lancet, 1995, 346: 530–536.
2. Wawer MJ et al. Control of sexually transmitted
diseases for AIDS prevention in Uganda: a
randomised community trial. Lancet, 1999,
353: 525–535.
3. Grosskurth H et al. Control of sexually
transmitted diseases for HIV-1 prevention:
understanding the implications of the Mwanza
and Rakai trials. Lancet, 2000, 355:
1981–1987.
4. Hudson CP. Community-based trials of sexually
transmitted disease treatment: repercussions
for epidemiology and HIV prevention. Bulletin
of the World Health Organization, 2001, 79:
48–58.
5. Mayaud P et al. Improved treatment services
significantly reduce the prevalence of sexually
transmitted diseases in rural Tanzania: results
of a randomised controlled trial. AIDS, 1997,
11: 1873–1880.
6. Orroth K et al. Syndromic STD treatment
reduces the proportion of incident HIV infections
attributable to these diseases in rural Tanzania.
AIDS, 2000, 14: 1429–1437.
7. O’Reilly KR, Gerbase AC. STI care: one of
many necessary approaches for prevention
of HIV infection. Bulletin of the World Health
Organization, 2001, 79: 58–59.
483Bulletin of the World Health Organization, 2001, 79 (5)
Letters
